# Immune and Endothelial-Related Extracellular Vesicles Are Associated with Corticosteroid Response and Mortality in Alcohol-Associated Hepatitis

**Authors:** Albert Guinart-Cuadra, Anna Brujats, Justyna Szafranska, Rubén Guerrero, Fernándo Dinamarca, Elisabet Cantó, Maria Poca, Eva Román, Elisabet Sánchez-Ardid, Javier Fajardo, Montserrat Camps, Maria Mulet, German Soriano, Àngels Escorsell, Juan M. Falcon-Perez, Esperanza Gonzalez, Andreu Ferrero-Gregori, Cristina Gely, Jorge Villalba, Ramón Bataller, Josepmaria Argemi, Rubén Osuna-Gómez, Silvia Vidal, Edilmar Alvarado-Tapias

PMC · DOI: 10.3390/ijms27031258 · International Journal of Molecular Sciences · 2026-01-27

## TL;DR

Extracellular vesicles in the blood of patients with alcohol-associated hepatitis may predict how well they respond to corticosteroids and their risk of death.

## Contribution

This study identifies extracellular vesicle markers linked to corticosteroid response and mortality in alcohol-associated hepatitis patients.

## Key findings

- EVs enriched in endothelial and monocyte markers correlate with corticosteroid response and mortality in AH.
- Platelet and endothelial EV markers are associated with corticosteroid response.
- B lymphocyte and endothelial EV markers are linked to mortality.

## Abstract

Alcohol-associated hepatitis (AH) is the most severe clinical manifestation of alcohol-associated liver disease. Corticosteroids are the only disease-specific therapy shown to improve short-term survival. Currently, no non-invasive markers are available to predict patient response to corticosteroids or long-term survival in AH. This study investigates whether surface antigens on plasma extracellular vesicles (EVs), key mediators of intercellular communication, can reflect the underlying immune dysregulation in AH and serve as prognostic markers. Patients with AH were prospectively enrolled between 2020 and 2024. Blood samples were collected before corticosteroid initiation during the first 24 h of hospitalization. EVs were characterized using nanoparticle tracking analysis, cryo-electron microscopy, and flow cytometry. Interleukin-6 (IL-6), soluble (s)CD62p, Circulating Vascular Cell Adhesion Molecule-1 (sVCAM), tumor necrosis factor receptor superfamily member 1 (TNRFS1a), and Intercellular Adhesion Molecule 1 (ICAM-1) were quantified by ELISA. Key outcome variables included response to corticosteroids and mortality. A total of 46 patients with AH and 28 healthy donors (HD) were included. EV concentration was significantly higher in AH patients than in HD (9.3 × 1011 [IQR 4–24] versus 2.4 × 1011 [IQR 2–4], p = 0.03). Specific EV antigens were associated with key clinical outcomes: CD20 and CD2 levels differed between patients with or without infections (bacterial, viral, and fungal) developed during hospitalization; CD40 and CD146 were elevated in patients who developed acute kidney injury. EVs enriched in monocyte (CD14) and T-reg (CD25) markers were associated with plasma IL-6 levels, while endothelial markers CD105 and CD146 correlated with sVCAM and sCD62p. EVs enriched in platelet (CD49e) and endothelial (CD31) markers were associated with corticosteroid response, whereas EVs enriched with endothelial (CD105 and CD146) and B lymphocyte (CD19) markers were associated with mortality. Overall, EVs enriched in endothelial and monocyte markers may represent a candidate non-invasive tool for predicting corticosteroid response and mortality in AH, aiding risk stratification and early identification of non-responders for timely transplant evaluation.

## Linked entities

- **Proteins:** IL6 (interleukin 6), ICAM1 (intercellular adhesion molecule 1), MS4A1 (membrane spanning 4-domains A1), CD2 (CD2 molecule), CD40 (CD40 molecule), MCAM (melanoma cell adhesion molecule), CD14 (CD14 molecule), IL2RA (interleukin 2 receptor subunit alpha), Eng (endoglin), ITGA5 (integrin subunit alpha 5), PECAM1 (platelet and endothelial cell adhesion molecule 1), CD19 (CD19 molecule)
- **Diseases:** acute kidney injury (MONDO:0002492), bacterial infection (MONDO:0005113), viral infection (MONDO:0005108)

## Full-text entities

- **Genes:** KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD14 (CD14 molecule) [NCBI Gene 929], IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, MCAM (melanoma cell adhesion molecule) [NCBI Gene 4162] {aka CD146, HEMCAM, METCAM, MUC18, MelCAM}, ITGA5 (integrin subunit alpha 5) [NCBI Gene 3678] {aka CD49e, FNRA, VLA-5, VLA5A}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}
- **Diseases:** infections (MESH:D007239), acute kidney injury (MESH:D058186), immune dysregulation (OMIM:614878), liver disease (MESH:D008107), fungal (MESH:D009181), AH (MESH:D006519)
- **Chemicals:** alcohol (MESH:D000438)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12897947/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12897947/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12897947/full.md

---
Source: https://tomesphere.com/paper/PMC12897947